02 Jun 2026
Marksans Pharma entered a definitive agreement to acquire 100% of QliniQ B.V. (Netherlands) for €7.5 million, pending completion conditions.
QliniQ reported €9.35 million revenue and €1.01 million net profit for FY ended December 2025. It carries zero debt and posted a 41% revenue CAGR over FY2023-FY2025. The acquisition gives Marksans front-end sales, marketing, distribution, EU GDP-licensed wholesale infrastructure, and direct access to insurer-led pharmaceutical tender channels in the Netherlands.